Regorafenib and TAS-102 for GI Cancers

Wafik El-Deiry, MD, PhD, FACP, Associate Dean for Oncologic Sciences at the Warren Alpert Medical School, Brown University, discusses his study on regorafenib with TAS-102 for multiple gastrointestinal cancers, particularly colorectal cancer.

He elaborates on the synergistic activity seen in the combination when used in cancer cells, as well as the vulnerability of colorectal cancer cells when exposed to TAS-102 at low doses.

Watch part 2 of our interview with Dr. El-Deiry here.